ProfileGDS5678 / 1440907_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 60% 60% 59% 58% 60% 58% 60% 64% 61% 62% 60% 60% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6186160
GSM967853U87-EV human glioblastoma xenograft - Control 23.6125360
GSM967854U87-EV human glioblastoma xenograft - Control 33.581160
GSM967855U87-EV human glioblastoma xenograft - Control 43.5185759
GSM967856U87-EV human glioblastoma xenograft - Control 53.4687758
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.66160
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6046658
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5922560
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8482364
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6070161
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6803662
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5458360
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6044260
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6004560